medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2017, Number 12

<< Back Next >>

Ginecol Obstet Mex 2017; 85 (12)

Clinical-biochemical characteristics of the primary ovarian failure. An institutional experience of 12 years

Sánchez-González CM, Martínez-Cruz N, Campos-Cañas JA, López-Rioja MJ, Hinojosa-Rodríguez KA, Recio-López Y

Language: Spanish
References: 30
Page: 799-808
PDF size: 411.36 Kb.


ABSTRACT

Objetive: Evaluate the clinical and biochemical characteristics of patients with primary ovarian failure.
Materials and Methods: An observational, cross-sectional and ambispective study carried out in patients treated between 2005 and 2017 in the National Institute of Perinatology with a diagnosis of primary ovarian failure. The patients were classified into groups according to the origin of the condition. The ANOVA test with Bonferroni correction was used to identify differences in the quantitative variables in the four study groups. A nonlinear model of CHAID type (χ2 automatic interaction detector) was performed, with the purpose of predicting the age at the beginning of the hormonal therapy according to the origin of the ovarian insufficiency.
Results: 98 patients were studied; 70 of them (71%) were classified idiopathic; 16 (17%) chromosomal and 12 (12%) autoimmune organ-specific. In the clinical characteristics, it was observed that patients with chromosomal etiology had spontaneous menopause before the age of 30 (80%); in those of surgical origin it was after 30 years (53.8%). In relation to bone mineral density, women with primary ovarian insufficiency of chromosomal origin were found to have less bone mass at the time of diagnosis compared to the other causes; the lumbar spine (L1 to L4) was the most affected.
Conclusion: The main cause of spontaneous primary ovarian failure in the sample studied was idiopathic, followed by chromosomal and organ-specific autoimmune. 12% had a family history, in first grade, of primary ovarian failure. The need for genetic counseling is obvious.


REFERENCES

  1. Nelson L. Primary Ovarian Insufficiency. N Engl J Med 2009; 360:606-614.

  2. Cooper A, Baker V, Sterling E, et al. The time is now for a new approach to primary ovarian insufficiency. Fertil Steril 2011; 95:1890-1897.

  3. Levy H. Premature Ovarian Failure. Intern Med News 2009; 60:606-614.

  4. Jagarlamudi K, Reddy P, Adhikari D, et al. Genetically modified mouse models for premature ovarian failure (POF). Mol Cell Endocrinol 2010;315:1-10.

  5. Nippita T, Baber R. Premature ovarian failure: a review. Climacteric 2007;10:11-22.

  6. Luborsky J, Meyer P, Sowers M, et al. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 2003;18:199-206.

  7. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod Update 2005;11:391-410.

  8. Pouresmaeili F, Fazeli Z. Premature ovarian failure: A critical condition in the reproductive potential with various genetic causes. Int J Fertil Steril 2014;8:1-12.

  9. Sommezer M, Oktay K. Fertility reservation in female patients. Hum Reprod Update 2004;10:251-266.

  10. Shelling AN. Premature ovarian failure. Reproduction 2010;140:633-641.

  11. Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J Mol Endocrinol 2010;45:257-279.

  12. La Marca A, Brozzetti A, Sighinolfi G, et al. Primary ovarian insufficiency: autoimmune causes. Curr Opin Obstet Gynecol 2010;22:277-282.

  13. Knauff E, Eijkemans M, Lambalk C, et al. Anti-Müllerian hormone, inhibin b, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 2009;94:786-792.

  14. Bakalov V, Anasti J, Calis K, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46, XX spontaneous premature ovarian failure. Fertil Steril 2005;84:958-965.

  15. Visser J, Schipper I, Laven J, et al. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol 2012;10:331-341.

  16. Cervera R, Balasch J. Bidirectional effects on autoimmunity and reproduction. Hum Reprod Update 2008; 14:359-366.

  17. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997;18:107-134.

  18. Robert D, Sergio P, Yukihiro K, et al. Serum gonadotropin and steroid patterns during the normal menstrual cycle. Am J Obstet Gynecol 1971;111:60-65.

  19. Popat V, Calis K, Kalantaridou S, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014;99:3418-3426.

  20. Welt C. Primary ovarian insufficiency: A more accurate term for premature ovarian failure. Clin Endocrinol 2008;68:499-509.

  21. Popat V, Calis K, Vanderhoof V, et al. bone mineral density in estrogen-deficient young. J Clin Endocrinol Metab 2009;94:2277-2283.

  22. Therapy H, Insufficiency PO. Committee opinion. Obstet Ginecol. 2017; 129:134-141.

  23. Faulkner K, Stetten E, Miller P. Discordance in patient classification using T-Scores. J Clin Densitom 1999;2:343-350.

  24. Fogle R, Stanczyk F, Zhang X, et al. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007;92:3040-3043.

  25. Knauff E, Westerveld H, Goverde A, et al. Lipid profile of women with premature ovarian failure 2008;15:919-923.

  26. Marino R, Misra M. Bone health in primary ovarian insufficiency. Semin Reprod Med 2011;29:317-327.

  27. Baber R. Primary ovarian insufficiency. Med Today 2014;15:73-75.

  28. Bidet M, Bachelot A, Touraine P. Premature ovarian failure: predictability of intermittent ovarian function and response to ovulation induction agents. Curr Opin Obstet Gynecol 2008;20:416-420.

  29. Shelling A. Premature ovarian failure. Reproduction 2010;140:633-641.

  30. Shalet SM. The impact of dose and route of estrogen administration on the somatotropic axis in normal women. J Clin Endocrinol Metab 2003;88:4668-4672.




2020     |     www.medigraphic.com